<DOC>
	<DOCNO>NCT00673127</DOCNO>
	<brief_summary>The combination ketaconazole hydrocortisone commonly use treatment prostate cancer . The purpose study determine addition drug call dutasteride approve combination make combination effective treat prostate cancer .</brief_summary>
	<brief_title>Ketoconazole , Hydrocortisone Dutasteride Asymptomatic Hormone Refractory Prostate Cancer</brief_title>
	<detailed_description>- Participants see study physician every four week short physical examination , blood test ask provide information condition . Every three month undergo bone scan . If CT scan obtain participant start study show evidence cancer , ask repeat test every three month . - Ketaconazole take orally three time day empty stomach . Hydrocortisone take orally morning night . Dutasteride take orally day . - Participants may remain study drug evidence disease progression .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Dutasteride</mesh_term>
	<mesh_term>Ketoconazole</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<criteria>Histologically document evidence prostate cancer ( needle biopsy prostatectomy ) . In abscence histologically document evidence prostate cancer , diagnosis must base elevated serum PSA metastatic lesion bone scan . Progressive HRPC define PSA increase baseline &gt; 25 % 5ng/ml new lesion bone/CT scan conventional androgen deprivation antiandrogen withdrawal . Evidence metastatic disease base positive CT bone scan require . PSA great equal 2ng/ml serum total testosterone less equal 50ng/ml Prior chemotherapy permit discontinue &gt; 4 week prior start therapy Prior therapy estrogen permit must discontinue &gt; 4 week prior registration ECOG Performance Status 02 Adequate renal function , hepatic function , bone marrow function outline protocol ECG show normal QT interval Prior therapy ketoconazole corticosteroid HRPC Major surgery radiation therapy within 4 week Strontium89 samarium153 therapy within 4 week Thromboembolism past 6 month Patients take drug may prolong QT interval present know risk Torsades de Pointes . Concomitant use drug know narrow therapeutic index CTP3A4 Drugs sensitive CYP3A4 substrates Alcohol drug dependence currently last 6 month</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>hormone refractory</keyword>
	<keyword>KHAD</keyword>
	<keyword>ketoconazole</keyword>
	<keyword>dutasteride</keyword>
	<keyword>hydrocortisone</keyword>
</DOC>